




medmix Beauty: Micro-bristle applicator pureIDENTITY

Our key figures


Our revenue was CHF 248.1 million, a decrease of 1.0% (increase 2.2% currency-adjusted, increase 1.3% organic), compared with H1 2022. We delivered an adjusted EBITDA margin of 20.0% and free cash flow of CHF –4.9 million.

Share of revenue by market segment
H1 2023



- 21.6% Dental
- 10.8% Drug Delivery
- 3.5% Surgery
- 29.3% Industry
- 34.8% Beauty

Share of revenue by market segment
H1 2022



- 28.5% Dental
- 9.5% Drug Delivery
- 2.7% Surgery
- 31.6% Industry
- 27.7% Beauty

Key figures

January 1 – June 30

millions of CHF	2023	2022 ¹⁾	Change in +/-%	+/-% adjusted ²⁾	+/-% organic ³⁾
Revenue	248.1	250.6	-1.0	2.2	1.3
Gross profit	82.0	99.2	-17.3		
Operating income (EBIT)	14.5	16.9	-14.5		
EBITDA	40.0	41.7	-4.0		
Adjusted EBITDA	49.7	60.1	-17.3		
Adjusted EBITDA margin	20.0%	24.0%			
Net income attributable to shareholders of medmix Ltd	7.3	9.2	-21.3		
Basic earnings per share (in CHF)	0.18	0.23	-21.1		
Free cash flow (FCF)	-4.9	14.2	n/a		
Net debt as of June 30 / December 31	164.0	156.7	4.7		
Net debt adjusted EBITDA ratio as of June 30 / December 31 ⁴⁾	1.73	1.49	16.1		
Employees (number of full-time equivalents) as of June 30 / December 31	2'245	2'067	8.6		

1) The numbers as of June 30, 2022, have been adjusted following the deconsolidation of medmix Poland. A reconciliation to the previously published numbers is provided in note 14.

2) Adjusted for currency effects.

3) Adjusted for acquisition and currency effects.

4) Adjusted EBITDA for the last 12 months